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Introduction
Sigma receptors were originally proposed by Martin and colleagues based upon studies with the benzomorphan (±)-N-allyl-normetazocine [(±)SKF-10047] (Martin et al., 1976) , but they are now defined as non-opioid, non-phencyclidine, haloperidol-sensitive, naloxone-inaccessible, (+)benzomorphan-selective binding sites (Quirion et al., 1992) , with two subtypes, sigma 1 and sigma 2 , based upon their binding selectivity profiles (Bowen et al., 1993) . Sigma binding sites are widely distributed across species and are present in almost all tissues, with highest expression in the central nervous system, immune system, kidney, and liver (Walker et al., 1992; Bowen, 2000; Gundlach et al., 1986) , as well as a wide range of tumors (Ryan-Moro et al., 1996; Vilner et al., 1995; Aydar et al., 2004; Spruce et al., 2004) .
The sigma 1 binding site has been cloned from guinea pig (Hanner et al., 1996) , human (Kekuda et al., 1996) , mouse (Pan et al., 1998; Seth et al., 1997) , and rat (Seth et al., 1998; Mei and Pasternak, 2001) , showing greater than 80% amino acid homology to each other, but no structural homology with any traditional receptor family. Sigma receptors physically associate with diverse cellular systems, including lipid microdomains (Hayashi and Su, 2003) , Kv 1.4 potassium channels (Aydar et al., 2002) and NMDA receptors (Martina et al., 2007; Monnet et al., 1996) , and it has MOL #57083 analgesia. Although, haloperidol has high affinity for both sigma 1 and dopamine D 2 receptors, the continued ability of haloperidol to potentiate opioid analgesia in dopamine D 2 receptor knockout mice further supports a direct sigma action (King et al., 2001 ).
Opioid receptors are heterotrimeric G-protein coupled receptors (GPCR) whose functionality is determined by macromolecular receptor assemblies comprising receptors and G-proteins, as well as associated cellular factors such as regulators of G-protein signaling (RGS), various receptor activity modifying proteins (RAMP), and G-protein-coupled receptor kinases (GRKs) (Hollinger and Hepler, 2002; McLatchie et al., 1998; Pitcher et al., 1998) . The complex network of proteinprotein interactions involved in GPCR signaling implicates a growing list of cytosolic and membrane bound signal modifying proteins involved in various cellular second messenger systems. What is more, allosteric drug interactions add to the complexity of regulating ternary structures comprising GPCR and associated factors (reviewed in (Christopoulos and Kenakin, 2002) .
Here, we demonstrate a physical and functional association of sigma 1 receptors with mu opioid receptors. We show that sigma 1 receptors directly associate with opioid receptors and that through this association, sigma selective antagonists can potentiate opioid induced cell signaling.
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with a triple amino-terminal Flag (DYKDDDD) epitope tag was generated by cloning into the p3XFlag expression vector (Sigma-Aldrich) as described (Pan et al., 2002) .
Immunoprecipitation and immunoblot analysis. Cells were harvested in cold phosphate buffered saline solution containing 2mM EDTA (PBS/EDTA), washed twice, and lysed for 30 min at 4°C in a solubilization buffer containing 0.5% Nonidet-P40, 50mMTris-HCl pH 7.4, 150mM
NaCl supplemented with a protease inhibitor cocktail (Roche). The detergent soluble fraction was obtained after centrifugation at 4°C for 10 minutes at 20,000 x g. The clarified Nonidet P 40 soluble cell lysate was used for immunoprecipitation with either 5 μ g of agarose-coupled rabbit anti-HA polyclonal antiserum sc-805 (Santa Cruz Biotechnology) or 2 μ g of agarose-coupled anti-FLAG(M2) mouse monoclonal antibody (Sigma Aldrich). Immunoprecipitated fractions and whole cell lysates (~10μg protein) were separated on 10% sodium dodecyl sulphate (SDS) polyacrylamide gels and transferred electrophoretically to nitrocellulose. Membranes were immunoblotted with either a horseradish peroxidase-conjugated rabbit anti-HA antibody (Santa Cruz Biotechnology) or a mouse anti-FLAG antibody (Sigma Aldrich). Immunoreactive proteins were visualized using the enhanced chemiluminescence detection system (GE Healthcare).
RNAi knockdown of sigma 1 . BE(2)-C cells were transfected with non-specific control or human sigma 1 receptor selective siRNA (Santa Cruz Biotechnologies). Oligofectamine (InVitrogen) was used as the siRNA transfection reagent, according to manufacturer suggested protocol. Cells were harvested and membranes prepared, as described above, 96 hours post- 
Results
Interaction of sigma ligands with opiate binding sites
Since sigma drugs potently modulate opiate analgesia in mice and rats (Chien and Pasternak, 1994; Mei and Pasternak, 2002) , we first determined whether sigma ligands directly affected opioid receptor binding. Sigma 1 binding is stereoselective. Although (-)pentazocine labels mu and kappa opioid binding sites with high affinity, it has only modest affinity for sigma sites. Conversely, (+)pentazocine selectivity labels sigma 1 receptors (K i 1.8 nM) approximately 500-fold more potently than mu opioid sites (K i > 700 nM) and over 30-fold more potently than kappa 1 binding sites (Chien et al., 1997) . Similarly, the sigma ligand BD1047 shows poor affinity for opioid binding sites (K i >1000 nM) while labeling sigma 1 sites with very high affinity (K i 0.9 nM) (Matsumoto et al., 1995 (Fig. 3) .
Inclusion of BD1047 shifted the dose-response curve to the left, documenting the ability of sigma 1 systems to influence non-opioid G-protein coupled receptors.
Sigma ligand modulation of mu and delta opioid-stimulated [ 35 S]GTPγS binding in BE(2)-C neuroblastoma cells
Mouse brain comprises a heterogeneous population of cell types and receptor systems. We next examined a more homogenous system, the human BE(2)-C neuroblastoma cell line that natively expresses mu opioid receptors (Standifer et al., 1994) . As in the brain, BD1047 alone had This article has not been copyedited and formatted. The final version may differ from this version. nM. Inclusion of a fixed concentration of BD1047 (10 nM) shifted the DAMGO dose-response curve over 4-fold to the left, yielding an EC 50 of only 13 nM (Fig 4B) . Despite this increase in DAMGO potency, BD1047 had no appreciable effect upon the maximal stimulation, a measure of efficacy, which was 69 ± 6 % above basal levels alone and 74 ± 3 % in the presence of BD1047.
While the selectivity of this antagonist strongly implicated a role for sigma 1 receptors in these actions, we next confirmed this using siRNA to downregulate sigma 1 receptors in BE (2) its response curve to the left over 15-fold and lowering its EC 50 value to 12 nM. As with the mu selective opioids, the maximal response in the presence of BD1047 (76 ± 4 % over basal) did not differ significantly from that of DPDPE alone.
In vivo, we observed opposing actions by the sigma 1 agonist (+)pentazocine and sigma 1
antagonists (Chien and Pasternak, 1994; Mei and Pasternak, 2002) . Whereas a sigma 1 antagonist potentiated opioid analgesia, (+)pentazocine diminished the opioid analgesic activity. We examined the effect of (+)pentazocine on opioid agonist-induced stimulation of [ 35 S]GTPγS binding. Despite using doses of (+)pentazocine up to 1 µM, we were unable to observe an effect of (+)pentazocine on DAMGO stimulation of [ 35 S]GTPγS. This inactivity of (+)pentazocine suggests that the sigma 1 receptors in the BE(2)-C cell line may already be in an "agonist"
conformation, limiting the activity of sigma 1 agonist ligands in this in vitro assay to sigma antagonists. 
Sigma ligand modulation of mu opioid
Physical association of sigma 1 and opioid receptors
The [ 35 S]GTPγS binding studies strongly suggested a direct interaction between sigma 1 and opioid receptors. To determine whether this reflected a physical association between these two proteins within a complex, we performed co-immunoprecipitation experiments using epitopetagged receptors. The FLAG-epitope was attached to the N-terminus of MOR-1 while an HA-tag was attached to the C-terminus of the sigma 1 receptor and both were transfected into HEK cells.
Immunoblotting with an HA antibody revealed bands only following a pull-down from lysates of cells transfected with the HA-tagged sigma 1 receptor ( In the inverse controls, we saw a similar pattern with the FLAG pull-down of the FLAGtagged MOR-1 (Fig. 8B, To determine whether MOR-1 and the sigma 1 receptors were physically associated, we pulled down the sigma 1 proteins with an HA antibody and immunoblotted with a FLAG antibody against MOR-1 (Fig. 8A, left panel) . In this study, we observed three detectable forms of Flag- In the inverse pull-down experiment, we immunoprecipitated FLAG-MOR-1. When we then did an HA-immunoblot, we observed a band only in the cells co-expressing both proteins (Fig. 8B, left panel) . The middle panel shows that the Flag-band is not present in membranes from , 1994; Chien and Pasternak, 1995) , which would be consistent with differing ratios of agonist/antagonist conformations of the sigma 1 receptor in these strains.
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We had initially anticipated that the sigma 1 antagonists would increase the affinity of the opioid for the receptor, but this was not the case. Since the affinity of the opioid is not influenced by the sigma ligand, the enhanced activation of G-proteins seems due to an increase in the intrinsic activity of the opioid since the maximal response can be achieved at lower receptor occupancy. It also is consistent with an increase in spare receptors in that a maximal response can be seen with occupation of a smaller fraction of receptors. The similar response with two other G-protein coupled receptors, the delta opioid receptor and the muscarinic acetylcholine receptor, raises the possibility that these sigma receptor actions may extend to other GPCR systems.
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